<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data from a 20-week trial comparing insulin detemir and neutral protamine Hagedorn (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>) insulin in insulin-naïve people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were analyzed using willingness-to-pay (WTP) data, a proxy for patient preference </plain></SENT>
<SENT sid="1" pm="."><plain>The advantages of insulin detemir relative to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin with respect to a lower <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> rate and less <z:mp ids='MP_0005456'>weight gain</z:mp> were associated with a value of €27.87 per month </plain></SENT>
</text></document>